This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bottomley, J. Articles by Massi-Benedetti, M. Search for Related Content Social Bookmarking                         What's this?

Review: PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events — economic implications?

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK, jmb{at}amygdala.uk.com

Andrew J Palmer

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK

Rhys Williams

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK

John Dormandy

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK

Massimo Massi-Benedetti

Amygdala Ltd, The Warren, Willian Road, Letchworth Garden City, Hertfordshire, SG6 2AA, UK

conomic value of medicines, medical devices and other technologies is an increasingly important consideration in healthcare management. Conducting high quality economic analyses alongside randomised controlled clinical trials (RCTs) is desirable since these offer timely information with high internal validity. The recent publication of the landmark PROactive study provides a relevant platform upon which to base a detailed economic evaluation of the possible additional benefit of pioglitazone over and above current best treatment in patients with type 2 diabetes with severe cardiovascular (CV) disease. Pioglitazone improved CV outcome and reduced the need to add insulin to existing therapy in individuals at high risk of further macrovascular events. The predefined economic analysis of this study using well-accepted methods will inform the cost effectiveness (CE) of pioglitazone confirming (or not) its value in the management of patients with type 2 diabetes with severe CV disease.

Key Words: type 2 diabetes • pioglitazone • insulin resistance • studies • cost-effectiveness • and guidelines. cardiovascular risk • severe cardiovascular disease • outcome studies • cost-effectiveness • and guidelines.

References

• Fisher M., Shaw K. Diabetes: a state of premature cardiovascular death. Pract Diab Int 2001;18:183-4.[CrossRef]
• Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;24:1047-53.
• Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001;322:1389-93.[Abstract/Free Full Text]
• Almdal T., Scharling H., Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischaemic heart disease, stroke and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422-6.[Abstract/Free Full Text]
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rubins HB, Robins SJ, Collins D. et al. for the Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.[Abstract/Free Full Text]
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes. UKPDS 33. Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bottomley JM Managing care of type 2 diabetes. Learnings from T2ARDIS. Br J Diabetes Vasc Dis 2001;1:68-72.[Abstract/Free Full Text]
• Williams R., Baxter H., Bottomley J. et al. CODE-2*UK: Our contribution to a European Study of the costs of Type 2 diabetes. Practical Diabetes International 2001;18:235-8.[CrossRef]
• Currie C., Morgan CL, Peters JR Patterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart 1997;78:544-54.[Abstract/Free Full Text]
• Baghurst A., Hopkinson PK, Maier W., Currie CJ An economic model of the long-term health care burden of Type II diabetes. Diabetologia 2001;44:2140-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Baghurst A., Hopkinson PK, Maslove L., Currie CJ The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabetic Medicine 2002;19(suppl 4):1-5.[Web of Science][Medline] [Order article via Infotrieve]
• Caro JJ, Ward AJ, O'Brien JA Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002;25:476-81.[Abstract/Free Full Text]
• National Diabetes Data Group. Diabetes in America. 2nd ed. 1995. National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468.
• Improving Diabetes Services - The NSF Two Years on, Department of Health Diabetes Team, 23 March 2005. Accessed on www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialcareTopics/Diabetes
• Haffner SM, D'Agostino R. Jr, Mykkanen L. et al. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care 1999;22:562-8.[Abstract]
• Campbell IW, Purcell H. The silent sextet. Br J Diabetes Vasc Dis 2001; 1:3-6.[Free Full Text]
• UK Prospective Diabetes Study (UKPDS) Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes. UKPDS 40. BMJ 1998;317:720-6.[Abstract/Free Full Text]
• Gray A., Raikou M., McGuire A. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial. UKPDS Group 41. BMJ 2000; 320:1373-8.[Abstract/Free Full Text]
• White JR Economic considerations in treating patients with type 2 diabetes mellitus. Am J Health System Pharm 2002;59(suppl 9):S14-S17.[Abstract/Free Full Text]
• Wagner EH, Sandhu N., Newton KM, McCullough DK, Ramsey SD, Grohaus LC Effects of improved glycemic control on health care costs and utilization. JAMA 2000;285:182-9.[CrossRef][Web of Science]
• Testa MA, Simonson DC Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes: a randomised, controlled clinical trial. JAMA 1998;280:1490-6.[Abstract/Free Full Text]
• Meier JL, Swislocki AL, Lopez JR, Noth RH, Bartlebaugh P., Siegel D. Reduction in self-monitoring of blood glucose in persons with type 2 diabetes results in cost savings and no change in glycemic control. Am J Manag Care 2002;8:557-65.[Web of Science][Medline] [Order article via Infotrieve]
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UKPDS Group. Lancet 1998;352:854-65.
• Clarke PM, Gray AM, Briggs A., Stevens RJ, Matthews DR, Holman R. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes. UKPDS 72. Diabetologia 2005;48:868-77.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gaede P., Vedel P., Larsen N., Jensen GV, Parving HH, Pedersen O.l. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.[Abstract/Free Full Text]
• Ukpds 37. Quality of life in Type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control. UKPDS Study Group. Diabetes Care 1999;22:1125-36.[Abstract/Free Full Text]
• Ukpds 62. Clarke P., Gray A., Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D. Medical Decision Making 2002;22:340-9.[Abstract/Free Full Text]
• Baghurst A., Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Economics 2005; 14:217-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Coffey JT, Brandle M., Zhou H. et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-43.[Abstract/Free Full Text]
• The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54.[Abstract/Free Full Text]
• Derosa G., Cicero AF, Gaddi A. et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26:744-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Chiquette E., Ramirez G., Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104.[Abstract/Free Full Text]
• Tilden DP, Mariz S., O'Bryan-Tear G., Diamantopoulos A. A lifetime economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Poster presentation ISPOR 2005, Florence, November 2005.
• Pyorala K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.[Abstract]
• UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. (UKPDS 38). BMJ 1998;317:703-13.[Abstract/Free Full Text]
• Kannel WB, Neaton JD, Wentworth D. et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT Multiple Risk factor Intervention Trial. Am Heart J 1986;112:825-36.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hansson L., Zanchetti A., Carruters SG et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Feinglos MN, Bethal MA Therapy of type 2 diabetes, cardiovascular death and the UGDP. Am Heart J 1999;138:S346-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Clarke P., Gray A., Adler A. et al. Cost effectiveness analysis of intensive blood glucose control with metformin in overweight patients with Type II diabetes (UKPDS 51). Diabetologia 2001;44:298-304.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Clarke P., Gray A., Legood R., Briggs A., Holman R. The impact of diabetes-related complications on healthcare costs (UKPDS Study 65). Diabetic Medicine 2003;20:442-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nyman JA, Martinson MS, Nelson D. et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol. Arch Intern Med 2002;162:177-82.[Abstract/Free Full Text]
• Schädlich PK, Brecht JG, Rangoonwala B., Huppertz E. Cost effectiveness of Ramipril in patients at high risk for cardiovascular events. Economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective. Pharmacoeconomics 2004;22:955-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Grover SA, Alexander CM, Coupla L., Weiss TW, Zowall H., Gomes DRJ. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50.[Abstract/Free Full Text]
• Jönsson B., Cook JR, Pedersen TR The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999;42:1293-301.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Brandle M., Davidson MB, Scriger DL, Lorber B., Herman WH Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 2003;26:1796-801.[Abstract/Free Full Text]
• Jönsson B., Hansson L., Stålhammer N.-O. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Int Med 2003;253:472-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Continued on page 70 Continued from page 68
• Rippin JD, Barnett AH, Bain SC Cost-effective strategies in the prevention of diabetic nephropathy. Pharmacoeconomics 2004;22:9-28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Palmer AJ Tucker DM Valentine WJ Roze S. Gabriel S. Cordonnier DJ Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies Nephrology Dialysis Transplantation 2005; 20:1103-09.[Abstract/Free Full Text]
• Burgess ED, Carides GW, Girth WC, Marentette MA, Chabot I. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Can J Cardiol 2004;20:613-18.[Web of Science][Medline] [Order article via Infotrieve]
• Charbonnel B., Dormandy J., Erdmann E., Massi-Benedetti M., Skene A.: The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive). Diabetes Care 2004;27:1647-53.[Abstract/Free Full Text]
• see www.proactive-results.com
• Dormandy JA, Charbonnel B., Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• A desktop guide to type 2 diabetes mellitus: European Diabetes Policy Group 1999. Diabet Med 1999;16:716-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Palmer AJ, Roze S., Valentine WJ et al. The CORE Diabetes Model: Projecting Long-term outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinions 2004;20:S5-S26.
• Palmer AJ, Roze S., Valentine W. et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S27-S40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Saydah SH, Fradkin J., Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42.[Abstract/Free Full Text]
• National Diabetes Audit. Key findings about the quality of care for people with diabetes in England. National Clinical Audit Support Programme. September 2005. Document Reference: 2005-IC-0025. Report available at www.icservices.nhs.uk/ncasp/pages/audit_topics/diabetes
• Improving Diabetes Services - The NSF Two Years on, Department of Health Diabetes Team, 23 March 2005. Accessed on www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialcareTopics/Diabetes
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE sub-study. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heart Protection Study Collaborative Group. MRC/BHF Heart protection Study of cholesterol-lowering with simvastatin in 5953 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 2, 63-70 (2006)
DOI: 10.1177/14746514060060020401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bottomley, J. Articles by Massi-Benedetti, M. Search for Related Content Social Bookmarking                         What's this?